UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB/A
AMENDMENT NO. 2 TO FORM 10-KSB
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 1996
Commission file number 0-23280
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Name of small business issuer as specified in its charter)
Delaware 94-3049219
(State of incorporation) (IRS Employer Identification No.)
1387 Marina Way South
Richmond, California 94804
(Address of principal executive offices)
(510) 215-8000
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b)
of the Act: None Securities registered
pursuant to Section 12(g) of the Act:
Common stock $.001 Par Value
(Title of class)
Check whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days:
Yes X No
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation SB contained herein, and no disclosure will be contained, to
the best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. X
Registrant's revenues for its most recent fiscal year were $506,242.
As of June 30, 1996, the Registrant had 6,512,485 shares of Common Stock,
$.001 par value, outstanding, and the aggregate market value of the shares held
by non-affiliates on that date was $43,145,213 based upon the last sale price of
the Issuer's Common Stock reported on the Nasdaq National Market.
<PAGE>
PART III
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K
(C) EXHIBITS
The following exhibits are incorporated by reference or filed as part of
this amendment to report.
EXHIBIT
NUMBER DESCRIPTION
- --------------------------------------------------------------------------------
27 Financial Data Schedule
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, this
Amendment to Report has been signed below by the following persons on behalf of
the Registrant and in the capacities and on the dates indicated.
Dated: November 1, 1996
Neurobiological Technologies, Inc.
/s/ Jeffrey S. Price
---------------------
President, Chief Executive Officer
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND> THE SCHEDULE CONTAINS SUMMARY FINANCIAL
INFORMATION EXTRACTED FROM BALANCE SHEET
AND INCOME STATEMENTS DATED 6/30/96
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> JUN-30-1996
<PERIOD-START> JUL-01-1995
<PERIOD-END> JUN-30-1996
<CASH> 4,602,815
<SECURITIES> 6,157,643
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 9,582,390
<PP&E> 356,660
<DEPRECIATION> 127,393
<TOTAL-ASSETS> 11,392,363
<CURRENT-LIABILITIES> 893,152
<BONDS> 0
<COMMON> 29,302,546
0
0
<OTHER-SE> (18,803,335)
<TOTAL-LIABILITY-AND-EQUITY> 11,392,363
<SALES> 0
<TOTAL-REVENUES> 506,242
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 5,717,685
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (5,211,443)
<INCOME-TAX> 0
<INCOME-CONTINUING> (5,211,443)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,211,443)
<EPS-PRIMARY> (1.05)
<EPS-DILUTED> (1.05)
</TABLE>
